Study wrapper · #1007
Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?
Editor's note
A hypothesis and research-agenda paper focused on amylin receptor agonists, with cagrilintide (including the CagriSema combination) as a central example. It proposes mechanisms linking amylin therapy to the renin-angiotensin system but presents no new experimental data, instead outlining studies to test its ideas. It is a forward-looking mechanistic commentary rather than an evidence report, though cagrilintide is genuinely central to the discussion.
Plain-language abstract
This hypothesis paper proposes that amylin-based therapies such as cagrilintide may activate the renin-angiotensin system, and that combining them with blood-pressure medications could redirect that activation toward a protective pathway. The authors outline preclinical and clinical studies to test the idea.